For example, in the IMpower150 trial, the addition of atezolizumab to bevacizumab and chemotherapy in patients with EGFR‐TKI drug‐resistant NSCLC led to improved efficacy.22 This evidence concerns the gene EGFR and non-small cell lung carcinoma.